Pfizer Signs Long-Term Agreement to Supply Prevenar 13 to The World’s Poorest Countries
Pfizer Inc. (NYSE:PFE) has signed a 10-year Provisional Supply Agreement to supply Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company’s 13-valent pneumococcal conjugate vaccine, for infants and young children in the world’s poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease.
Original Source of Pfizer Signs Long-Term Agreement to Supply Prevenar 13 to The World’s Poorest Countries
